NEW YORK (GenomeWeb News) – DHK Medical Products will distribute Arrayit's microarray-based genomic tests in India as part of a three-year deal announced today.
Under the terms of the agreement, DHK will offer Arrayit's tests through a planned expanding of a national network of 800 American Medical Center facilities. Arrayit, based in Sunnyvale, Calif., will offer its Variation Identification Platform microarray technology and blood card collection procedure to provide to patients in India information about their genetic predisposition to ailments such as hypertension, obesity, diabetes, cardiovascular disease, breast and ovarian cancer, and Parkinson's disease.
The technology identifies SNP variants in a patient's DNA. Results will be communicated to patients by DHK doctors, and DHK will provide on-site counseling and treatment options as necessary, the partners said.
Chandigarh, India-based DHK estimated that it will sell 25,000 genomic tests in the first year of the deal, 50,000 in the second, and 100,000 in the third year. Cumulative revenues to Arrayit stemming from the agreement are estimated at $16.8 million.